Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anti-epileptics Clear all
Completed Phase 2 Interventional Results available

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

NCT00938431
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
14
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 4 Interventional Results available

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

NCT02362373
View directory record Official record
Conditions
Epilepsy, Contraception
Interventions
levonorgestrel IUS
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 2 Interventional

Cannabidiol for Reduction of Brain Neuroinflammation

NCT05066308
View directory record Official record
Conditions
Back Pain, Depressive Symptoms
Interventions
CBD, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 1 Interventional Results available

Characterization of Epilepsy Patients BEEP 2b

NCT02707965
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 76 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 1Phase 2 Interventional

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

NCT00283556
View directory record Official record
Conditions
Malignant Glioma
Interventions
Irinotecan (Camptosar, CPT-11)
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Early Phase 1 Interventional

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

NCT02446431
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01837862
View directory record Official record
Conditions
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
Interventions
Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan
Drug
Lead sponsor
Julie Krystal
Other
Eligibility
1 Year to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Phase 2 Interventional

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

NCT05518578
View directory record Official record
Conditions
Epilepsy, Seizures, Epileptic
Interventions
SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Not applicable Interventional

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

NCT07445074
View directory record Official record
Conditions
Epilepsy, Seizure
Interventions
Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard
Other
Lead sponsor
University of Central Florida
Other
Eligibility
14 Years to 24 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

NCT03603639
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Placebo, E2730
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Boise, Idaho • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Nov 2, 2026, 4:09 PM EST
Withdrawn Phase 1Phase 2 Interventional

Diazepam Trial in GAD65 Associated Epilepsy

NCT05361447
View directory record Official record
Conditions
GAD 65 Antibody-associated Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
Interventions
Gabapentin gelatin capsules 300mg, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 1 Interventional

PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas

NCT00612651
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
Interventions
Temodar and SCH 66336
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Nov 2, 2026, 4:09 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

NCT06346262
View directory record Official record
Conditions
Epilepsy
Interventions
SMART RM, Valtoco Nasal Product
Behavioral · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Terminated No phase listed Observational

Evaluation and Treatment of Patients With Epilepsy

NCT00013845
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
2 Years and older
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 2, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

NCT05431595
View directory record Official record
Conditions
Delirium, Epileptics, Neuroleptics
Interventions
Haloperidol, Chlorpromazine, Valproate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Not applicable Interventional

Study of Transcranial Direct Current Stimulation to Treat Epilepsy

NCT05673915
View directory record Official record
Conditions
Focal Epilepsy, Generalized Onset Epilepsy, Sleep-related Epileptic Encephalopathy
Interventions
ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS), ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 2, 2026, 4:09 PM EST
Terminated Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01974700
View directory record Official record
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Nov 2, 2026, 4:09 PM EST
Recruiting Phase 4 Interventional

The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project

NCT07112365
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct)
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 2, 2026, 4:09 PM EST